Company intelligence / Profile preview

BiPER Therapeutics

Strasbourg, Grand Est, Francebiper-tx.com ↗

Ownership: Private
Employees: ~7
Development stage: Preclinical

Overview

BPR001-615 has demonstrated efficacy in vitro and in vivo as a single agent and in combination with chemotherapies and immunotherapies. The company aims to file a phase 1/2a Clinical Trial Application in Europe and an IND in the US by Q3 2025.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

BPR001

2 more assets in the full pipeline.

Beyond the preview

Go deeper on BiPER Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiPER Therapeutics.